{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T09:34:21Z","timestamp":1776850461406,"version":"3.51.2"},"reference-count":0,"publisher":"S. Karger AG","license":[{"start":{"date-parts":[[2017,8,11]],"date-time":"2017-08-11T00:00:00Z","timestamp":1502409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2017,8,11]],"date-time":"2017-08-11T00:00:00Z","timestamp":1502409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dev Pharmacol Ther"],"abstract":"<jats:p>The relationships between growth retardation and metabolic and hormonal\nparameters were studied in 7 children with fetal alcohol syndrome (FAS). Fasting blood\nconcentrations of TSH, T(4), T(3), FSH and LH were normal. Plasma prolactin concentrations\nafter chlorpromazine stimulation were normal. 3 children had abnormal oral glucose tolerance\ntests with increased plasma insulin response. Peak plasma growth hormone\nresponses to insulin-induced hypoglycemia were elevated in 5 patients. Fasting bioassayable\nserum somatomedin activity, determined in 6 patients, was elevated in 3 patients and\nnormal in 3 patients. Administration of hGH to 3 patients with FAS had little effect upon\nnitrogen retention and did not increase plasma insulin concentrations, although serum\nsomatomedin activity sharply increased in 1 patient evaluated for somatomedin response.\nThe data indicate that the growth defect in FAS is not due to deficiency of growthpromoting\nhormones, but rather to peripheral unresponsiveness.<\/jats:p>","DOI":"10.1159\/000457447","type":"journal-article","created":{"date-parts":[[2017,8,11]],"date-time":"2017-08-11T17:08:38Z","timestamp":1502471318000},"page":"232-241","source":"Crossref","is-referenced-by-count":50,"title":["Growth Retardation in Fetal Alcohol Syndrome"],"prefix":"10.1159","author":[{"given":"Salvador","family":"Castells","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erna","family":"Mark","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faika","family":"Abaci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ernest","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2017,8,11]]},"container-title":["Developmental Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000457447","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T08:34:14Z","timestamp":1776846854000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000457447"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,11]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1159\/000457447","archive":["Portico"],"relation":{},"ISSN":["0379-8305","2504-2505"],"issn-type":[{"value":"0379-8305","type":"print"},{"value":"2504-2505","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,11]]}}}